Author: The Market Link

Microsalt plc (LSE:SALT), a leader in patented low-sodium salt solutions, has announced record first-half 2025 revenue, reflecting growing international traction and increasing demand from both established and new markets. In a recent interview with Ricki Lee on The Watchlist, CEO Rick Guiney discussed the company’s strategy for sustaining growth, strengthening partnerships, and capturing opportunities across global food and consumer markets.

A major driver of recent performance has been repeat orders from one of Microsalt’s largest customers, particularly across its divisions in Mexico and North America. Guiney explained that the company is reinforcing these relationships through direct engagement and a strengthened R&D platform. “Because of the size and importance of this customer, we’re making in-person visits and tailoring our solutions to ensure we meet their needs worldwide,” he said.

Microsalt is also gaining momentum in Asia, Australia, and South Africa. Guiney noted that entering new regions requires adapting to unique regulatory, cultural, and dietary dynamics. “Every geography has its own dietary preferences. Our research ensures we design the right formulas and flavour profiles to match local demand,” he explained.

Looking ahead, the company has set ambitious sales commitments for 2026 and 2027, supported by forward contracts and long-term customer relationships. “Our growth projections are solid because they’re based on existing customer commitments,” Guiney emphasized. “Once a customer goes low sodium, they can’t go back. That makes our business model very durable.”

Microsalt’s patented technology is a critical differentiator, providing both a competitive moat and scalability in a rapidly expanding market. “We’re the low-sodium specialists. This is all we do,” Guiney said. “If you walk through any grocery store, almost every product on the shelf is a candidate for sodium reduction. That’s the size of the opportunity.”

With global health authorities and regulators increasingly focused on reducing sodium consumption, Microsalt’s solutions are well-positioned to benefit from both policy support and consumer demand. For investors, the company offers exposure to a unique, patented product with global applicability and growing adoption across key markets.

For more on Microsalt’s growth and expansion strategy, visit microsaltinc.com.

Disclaimer:

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

---

On The Watchlist, ImmuPharma (LSE:IMM) CEO Tim McCarthy outlined why the Company’s newly filed patent P140 ‘immunormalizer’, could redefine treatment for autoimmune diseases — and why the market may still be underestimating its potential.

Key Takeaways from the Interview

• Breakthrough science: P140 is positioned as the first “immunormalizer,” a precision platform combining a rapid diagnostic with a therapy designed to restore immune balance instead of broadly suppressing it.
• Broad reach: Initially developed in lupus, P140 could address up to 50 autoimmune indications, potentially placing patients into remission with fewer side effects.
• Large addressable market: Autoimmune diseases represent a ~$100B global therapeutics market, with ~400M patients worldwide, plus a ~$10B diagnostics segment.
• Commercial momentum: Since the patent announcement, ImmuPharma’s share price has rallied. McCarthy believes this is “only the start,” with pharma partners already engaging and deal announcements expected by year-end.
• Solid funding runway: The Company has more than 12 months of cash on hand, bolstered by an ongoing equity facility with Lanstead, warrant exercises and R&D credits Future trials are expected to be financed by partners, reflecting ImmuPharma’s asset-light model.

---

Investment View

ImmuPharma’s P140 platform offers a differentiated angle in a crowded autoimmune market: it targets immune homeostasis rather than indiscriminately dampening immune responses. If upcoming partnerships confirm clinical and commercial traction, investors could see meaningful upside.

Risks remain — valuation debates, deal timing, and clinical execution — but McCarthy’s confidence in near-term licensing agreements suggests catalysts are on the horizon. For investors looking at innovative biotech plays with broad application potential, ImmuPharma merits close watch.

---

Disclosure:

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

During a recent appearance on The Watchlist, Atome PLC (LSE:ATOM) CEO Olivier Mussat discussed the company’s progress on its flagship Villeta low-carbon fertiliser project in Paraguay and the strategic importance of its offtake agreement with Yara International.

The definitive contract — already signed between the companies — gives Yara rights to purchase the entire output from Villeta for a minimum of ten years, for supply into a ready market for the plant’s production and reinforcing the project’s leading role in the emerging low-carbon fertilizer supply chain.

---

Key Points from the Interview

• Decarbonising fertilizers: Atome PLC, listed on the London Stock Exchange, positions itself as the first pure-play producer of low-carbon fertilizer. Fertilizer manufacturing and use currently generates more greenhouse gases than shipping and aviation sectors combined, creating a major opportunity for disruption.
• Villeta’s strategic location: Paraguay’s plentiful, low-cost hydropower will feed a facility designed to produce about 260,000 tonnes of green ammonia-based fertilizer annually. Its location near Brazil, Argentina, and Uruguay — a region consuming ~30M tonnes of nitrates per year — provides immediate demand for output.
• Yara agreement de-risks financing: Partnering with one of the world’s largest fertilizer companies validates Villeta’s commercial model, providing long-term revenues and supporting access to competitive project finance for the $465M build.
• Execution pathway: Land, permits, environmental licenses, power purchase agreements, and a fixed-price EPC contract with Casale are already in place. The focus now is closing debt and equity packages with development finance institutions such as IDB and FMO. A Final Investment Decision (FID) is expected later this year after which construction will begin.

---

Investment View

The Yara offtake gives Atome PLC a key foundation to advance the Villeta project and establishes the company as an leader in the wider green hydrogen and ammonia market.

With all major development risks addressed and project finance at an advanced stage, Atome PLC offers investors unique and increasingly de-risked exposure to the growing low-carbon agriculture market.

Upcoming catalysts include financial close, FID, and construction milestones leading to production within roughly 38 months of FID.

Disclosure:

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cadence Minerals (LSE:KDNC) is positioning itself for a pivotal year as it advances both its flagship Amapá iron ore project and the restart of the Azteca plant — a smaller but strategically important asset.

In a recent interview, CEO Kiran Morzaria explained how Azteca will act as a bridge toward Amapá’s full potential. While the Amapá project boasts a post-tax NPV of $1.97 billion, a 15-year mine life, and a planned production of 5.5 million tonnes of high-grade iron ore annually, Azteca is set to generate near-term cash flow. Backed by a $4.6 million offtake agreement — with Cadence contributing only 10–15% of that amount — the plant offers an efficient way to fund growth without overreliance on placings.

“Azteca is the bridge that gets us there,” Morzaria noted. “It’s a great step forward that allows us to move from Azteca to Amapá.”

Addressing Dilution Concerns

Shareholder worries about dilution remain common across the natural resources sector. Morzaria acknowledged that Cadence has, at times, relied on equity placings, but emphasized the company’s hybrid model: investment gains have historically funded much of its project pipeline.

For Azteca, the majority of financing is provided by the offtake partner rather than shareholders. The Azteca plant is expected to deliver around $32 million of cash flow, which will be reinvested directly into the development of the Amapá project. In addition, Cadence benefits from its 10–15% interest in the offtake structure, which is forecast to generate an internal rate of return approaching 70%. This creates a dual value stream: project reinvestment and exceptional returns to Cadence shareholders.

Cash Flow to Accelerate Development

The real strength of Azteca lies in its ability to produce cash from the very first shipment. Those revenues will flow directly into definitive feasibility studies, permitting, and early works at Amapá, reducing dependence on new equity. If ore volumes and recoveries outperform expectations, Azteca could even support the equity portion of Amapá’s project financing — protecting Cadence’s 36% interest in the world-class iron ore asset.

With Amapá’s scale (NPV $1.97 billion, IRR 56%) and low delivered costs to China, Cadence sees a clear value gap between its market capitalization and its stake in the project. The strategy is straightforward: generate cash, minimize dilution, and prove Amapá’s potential as a top-tier low-cost producer.

Disclaimer:

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.